Navigation Links
S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
Date:12/12/2011

nts.  At the six-month visit, a significant reduction (>2 point improvement in mean symptom score) was observed for MF-associated symptoms, including abdominal pain, bone pain, early satiety, worst fatigue, inactivity, night sweats and pruritus.

"There is a significant medical need in the treatment of myelofibrosis and the results from pacritinib's clinical trials encourage us to quickly move forward with a global Phase 3 study to further demonstrate pacritinib's clinical benefits and consequently capture an important niche market in the treatment of MF," said Tamar Howson, interim CEO and board member of S*BIO.

Pacritinib is a small molecule JAK2-selective kinase inhibitor, which has demonstrated high potency in preclinical models against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in myeloproliferative disorders such as MF. It is estimated that approximately 50% of patients with MF possess the JAK2 mutation.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs including kinases and histone deacetylases (HDAC). Pacritinib, or SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has completed Phase 2 trials for MF. It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, pracinostat (SB939), is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and o
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. University Hospitals Seidman Cancer Center Tests Novel Drug That Makes Brain Tumors Glow Hot Pink
2. Novelos Therapeutics Prices $5.9 Million Public Offering
3. MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
4. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
5. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
6. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
7. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
8. CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
9. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
10. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
11. Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), today ... of the study presented by a prominent heart ... and concurrently published by the Journal of ... in patients with moderate to severe chronic heart ... the heart,s ability to pump blood, and reduces ...
(Date:9/2/2014)... , Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood instrumentation and consumables to the medical, research ... , Chairman and Chief Executive Officer, will present at ... 10, 2014 at 10:20 a.m. ET. The conference will ... New York City . ...
(Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
Breaking Medicine Technology:ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... Reportlinker.com announces that a new market research report ... European Markets for Interventional Cardiology Devices 2011 ... In 2010, the European markets ... euro1.5 billion. In 2010, the fastest growing European ...
... MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ -- ... today announced the publication of results from the Phase ... in the peer-reviewed journal ,Headache., The manuscript, titled MAP0004, ... Acute Treatment of Migraine, has been posted online and ...
Cached Medicine Technology:Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 2Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 3Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 4Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 5Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 6Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 7Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 8Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 9Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 10Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 11Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 12Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 13Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 14Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 15Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 16Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 17Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 18Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 19Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 20Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 21Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 2Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 3Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 4
(Date:9/2/2014)... 2014 Cancer screening is a critical approach for ... more treatable. But while there are already existing ways ... a great need for even more safe, cheap and ... a team of researchers led by Shaoxin Li at ... of a new, non-invasive method to screen for prostate ...
(Date:9/2/2014)... Warwick, R.I. (PRWEB) September 02, 2014 As ... analyze shifts in an industry and predict change. Fortunately for ... years, enabling him to identify markets that are eager for ... “My knowledge of the hearing aid market indicated it was ... to the consumer,” Sapio explained. As a result, he took ...
(Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
(Date:9/2/2014)... CA (PRWEB) September 02, 2014 ... and collaboration, announces partnership with NTT DoCoMo ... business customers. Splashtop Business Lite is included in ... is a remote desktop software that empower users to ... Splashtop has garnered over 18 million users worldwide. ...
(Date:9/2/2014)... 2014 West Hollywood cosmetic dentist ... for Invisalign. This special offer includes a free consultation ... determine their candidacy for the procedure and answer any ... may also be eligible for the Summer Invisalign special, ... the month of August, patients who choose Invisalign will ...
Breaking Medicine News(10 mins):Health News:New method for non-invasive prostate cancer screening 2Health News:David Sapio Launches Zounds Hearing Franchise 2Health News:Many nurses unprepared to meet dying patients 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2
... cheap, ruggedized forensics cameras will survive., , , ... , , ... , , , ... , , , , Lights, Camera, Ka-Boom! ...
... Makes Expo SplashPLEASANT GROVE, Utah, March 9 What,s ... Myo-Med ( www.myomed.com ), names like Tom Brady, LaDainian ... to truly helping people. Endorsements by professional athletes of ... these athletes actually used the product for a couple ...
... Stars at the Bal Harbour Shops Raised More Than ... - Seal and The Pointer Sisters Performed to a ... CollectionTommy Lee Jones, Gloria & Emilio Estefan, Anna Kournikova, ... Pat Riley Among the Stars in AttendanceMIAMI, March 9 ...
... Services, Inc. (NYSE: WST ) today announced that ... and William Federici, Chief Financial Officer, will be presenting at ... March 11, 2009 in Miami Beach. A copy of the ... of the Company,s website at www.westpharma.com and the ...
... following is a statement by Reverend Dr. Carlton ... for Reproductive Choice (RCRC) congratulates President Obama for ... funding of human embryonic stem cell research. This ... respects diverse religious and moral views and a ...
... 9 Speaker Nancy Pelosi issued the following ... lifting the Bush Administration,s restrictions on federally financed human ... on federal funding for stem cell research, President Obama ... family in America is just one diagnosis, one phone ...
Cached Medicine News:Health News:Ka-Boom!!! 2Health News:Ka-Boom!!! 3Health News:Ka-Boom!!! 4Health News:Tom Brady Endorsed Pain Cream Returns to Natural Products Expo 2Health News:Destination Fashion 2009 Presented by Stewart Rahr - 2Health News:Destination Fashion 2009 Presented by Stewart Rahr - 3Health News:Religious Coalition for Reproductive Choice President Applauds Obama Stem Cell Policy 2
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
... Plasma Reagin card test ... and quantitative determination of ... plasma. Uses carbon particle ... reagin. Kits include 10-well ...
Medicine Products: